MoonLake Immunotherapeutics
NASDAQ Capital MarketTotal Valuation
MoonLake Immunotherapeutics carries a market capitalization of 1.66B, placing it among publicly traded companies globally. Its enterprise value stands at 972.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.66B |
| Enterprise Value | 972.66M |
Share Statistics
MoonLake Immunotherapeutics currently has 72.13M shares outstanding.
| Shares Outstanding | 72.13M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.31 |
| P/TBV Ratio | 4.84 |
| P/FCF Ratio | -5.49 |
| P/OCF Ratio | -5.49 |
Financial Position
MoonLake Immunotherapeutics maintains a current ratio of 8.60, meaning it holds 8.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.68, indicating elevated leverage, while an interest coverage ratio of -27.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 8.60 |
| Quick Ratio | 7.89 |
| Debt / Equity | 39.68 |
| Debt / EBITDA | -0.38 |
| Interest Coverage | -27.83 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -56.40 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1.08M |
| Effective Tax Rate | N/A |
Stock Price Statistics
MoonLake Immunotherapeutics's stock has declined approximately -62.55367% over the past 52 weeks. The 50-day moving average sits at 18.86, while the 200-day moving average is 15.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -62.55367% |
| 50-Day Moving Average | 18.86 |
| 200-Day Moving Average | 15.78 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -264.29M, while operating income came in at -267.37M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -267.37M |
| Pretax Income | -258.39M |
| Net Income | -257.08M |
| EBITDA | -264.29M |
| EBIT | -267.37M |
| Earnings Per Share (EPS) | -3.93 |
Balance Sheet
MoonLake Immunotherapeutics holds 357.92M in cash and equivalents against 100.80M in total debt, resulting in a net debt position of -199.47M. Total book value stands at -532.61M, with working capital of 350.53M providing operational flexibility.
| Cash & Cash Equivalents | 357.92M |
| Total Debt | 100.80M |
| Net Debt | -199.47M |
| Equity (Book Value) | -532.61M |
| Book Value Per Share | -8.07 |
| Working Capital | 350.53M |
Cash Flow
MoonLake Immunotherapeutics produced -224.15M in operating cash flow over the past twelve months.
| Operating Cash Flow | -224.15M |
| Capital Expenditures | N/A |
| Free Cash Flow | -224.15M |
| FCF Per Share | -3.40 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.42 |
| FCF Yield | -18.23 |
Scores
MoonLake Immunotherapeutics posts an Altman Z-Score of 2.03, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.03 |